The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Regulation of chromatin structure by site-specific histone H3 methyltransferases
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845 · cited 3×
“The conserved histidine residue in this consensus sequence has been shown to be critical for the methyltransferase activity of all these proteins (Rea et al., 2000; Tachibana et al., 2001; Wang et al., 2001; Nishioka et al., 2002).”
BackgroundThe polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · cited 5×
“More recently, Varambally et al. (2002) demonstrated that siRNA duplexes targeting EZH2 in the prostate cell line PC3 induced significant growth inhibition.”
BackgroundMethodInfluentialKleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649 · cited 4×
“The number in the right upper corner represents the combined cell fraction in S and G2/M stages of the cell cycle, while the number in the left corner represents the apoptotic fraction Oncogene 2003; Kleer et al., 2003).”
BackgroundInfluentialKuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Tachibana, M., Sugimoto, K., Fukushima, T., & Shinkai, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101914200 · Cited by 784 · cited 3×
“The conserved histidine residue in this consensus sequence has been shown to be critical for the methyltransferase activity of all these proteins (Rea et al., 2000; Tachibana et al., 2001; Wang et al., 2001; Nishioka et al., 2002).”
BackgroundPoint Mutations in the WD40 Domain of Eed Block Its Interaction with Ezh2
Denisenko, O., Shnyreva, M., Suzuki, H., & Bomsztyk, K. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5634 · Cited by 98
Cited by
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Varambally, S., Cao, Q., Mani, R.-S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., et al. (2008) · Science · doi:10.1126/science.1165395 · Cited by 1,052
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Simon, J. A., & Lange, C. A. (2008) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2008.07.010 · Cited by 855
Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Wilson, B. G., Wang, X., Shen, X., McKenna, E. S., Lemieux, M. E., Cho, Y.-J., Koellhoffer, E. C., Pomeroy, S. L., Orkin, S. H., & Roberts, C. W. M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.006 · Cited by 654
Chromatin remodeling and cancer, part I: covalent histone modifications
Wang, G. G., Allis, C. D., & Chi, P. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.003 · Cited by 418
Lu, J., He, M.-L., Wang, L., Chen, Y., Liu, X., Dong, Q., Chen, Y.-C., Peng, Y., Yao, K.-T., Kung, H.-F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1850 · Cited by 381
Doherty, L. F., Bromer, J. G., Zhou, Y., Aldad, T. S., & Taylor, H. S. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0015-9 · Cited by 338
Cohen, I., Rider, P., Carmi, Y., Braiman, A., Dotan, S., White, M. R., Voronov, E., Martin, M. U., Dinarello, C. A., & Apte, R. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915018107 · Cited by 329
Histone methyltransferases in cancer
Albert, M., & Helin, K. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.10.007 · Cited by 306
Cancer epigenetics: linking basic biology to clinical medicine
Tsai, H.-C., & Baylin, S. B. (2011) · Cell Research · doi:10.1038/cr.2011.24 · Cited by 297
Alajez, N. M., Shi, W., Hui, A. B. Y., Bruce, J., Lenarduzzi, M., Ito, E., Yue, S., O'Sullivan, B., & Liu, F.-F. (2010) · Cell Death & Disease · doi:10.1038/cddis.2010.64 · Cited by 160
Smits, M., Mir, S. E., Nilsson, R. J. A., van der Stoop, P. M., Niers, J. M., Marquez, V. E., Cloos, J., Breakefield, X. O., Krichevsky, A. M., Noske, D. P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016282 · Cited by 118
“EZH2-regulated genes indicated that EZH2 can act as a bona fide oncogene that stimulates an ‘active’ cell status by trimethylating lysine 27 of histone H3 [26,40–46].”
BackgroundActivation of the Enhancer of Zeste Homologue 2 Gene by the Human Papillomavirus E7 Oncoprotein
Holland, D., Hoppe-Seyler, K., Schuller, B., Lohrey, C., Maroldt, J., Dürst, M., & Hoppe-Seyler, F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1134 · Cited by 99
Murphy, T. M., O’Donovan, A., Mullins, N., O’Farrelly, C., McCann, A., & Malone, K. (2015) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000055 · Cited by 98
STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner
Sun, S., Wu, Y., Guo, W., Yu, F., Kong, L., Ren, Y., Wang, Y., Yao, X., Jing, C., Zhang, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2248 · Cited by 93
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
Rizq, O., Mimura, N., Oshima, M., Saraya, A., Koide, S., Kato, Y., Aoyama, K., Nakajima-Takagi, Y., Wang, C., Chiba, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2735 · Cited by 83
“Results UNC1999, a dual inhibitor of EZH2 and EZH1, inhibits the growth of multiple myeloma cells Confirming a previous report by an siRNA method (14), knockdown of EZH2 by shRNA using lentiviral vectors leads to growth of inhibition in H929 myeloma cells following reduction inH3K27me3 levelswithno significant change…”
Background
Metadata
- Authors
- Croonquist, P. A., & Van Ness, B.
- Venue
- Oncogene
- Published
- 2005-07-11
- Volume
- 24
- Issue
- 41
- Pages
- 6269-6280
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2024873523
- Cited by
- 162
- References
- 8
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.